NCT06962449

Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

Analysis of Treatment Patterns and Clinical Outcomes After First-Line Treatment With Tislelizumab in Advanced NSCLC: A Real-World Observational Study

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC. Based on the inclusion and exclusion criteria, patients with advanced NSCLC who received first-line Tislelizumab treatment and progressed will be retrospectively screened and collected from January 1, 2020, to the study initiation date, and followed up for observation.

Conditions

• Non-Small-Cell Lung Cancer
• Non-Small-Cell Lung Cancer Stage IV

Timeline

• Start date: 2024-08-16
• Primary completion: 2025-06-30
• Completion: 2026-12-31
• First posted: 2025-05-08
• Last updated: 2025-05-08

Locations

1 site across 1 country: China